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Abstract
Background: Research concerning the association between use of antidepressants and incidence of suicide has yielded
inconsistent results and is the subject of considerable controversy. The first aim is to describe trends in the use of
antidepressants and rates of suicide in Europe, adjusted for gross domestic product, alcohol consumption, unemployment,
and divorce. The second aim is to explore if any observed reduction in the rate of suicide in different European countries
preceded the trend for increased use of antidepressants.
Methods: Data were obtained for 29 European countries between 1980 and 2009. Pearson correlations were used to
explore the direction and magnitude of associations. Generalized linear mixed models and Poisson regression distribution
were used to clarify the effects of antidepressants on suicide rates, while an autoregressive adjusted model was used to test
the interaction between antidepressant utilization and suicide over two time periods: 1980–1994 and 1995–2009.
Findings: An inverse correlation was observed in all countries between recorded Standardised Death Rate (SDR) for suicide
and antidepressant Defined Daily Dosage (DDD), with the exception of Portugal. Variability was marked in the association
between suicide and alcohol, unemployment and divorce, with countries depicting either a positive or a negative
correlation with the SDR for suicide. Every unit increase in DDD of an antidepressant per 1000 people per day, adjusted for
these confounding factors, reduces the SDR by 0.088. The correlation between DDD and suicide related SDR was negative in
both time periods considered, albeit more pronounced between 1980 and 1994.
Conclusions: Suicide rates have tended to decrease more in European countries where there has been a greater increase in
the use of antidepressants. These findings underline the importance of the appropriate use of antidepressants as part of
routine care for people diagnosed with depression, therefore reducing the risk of suicide.
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Introduction
Antidepressant use has continually increased in most European
countries since the advent of selective serotonin reuptake inhibitors
(SSRIs). Between 2000 and 2010 rates of use in Europe have
continued to increase, with the highest DDD rates seen in Iceland,
Denmark and Portugal [1]. Suicide rates vary greatly across the
European Economic Area, but between 1980 and 2000 suicide
rates fell in all of the EU-15 countries plus Norway, with the
exceptions of Ireland and Spain [2]. From 1995 to 2010, the same
decrease in suicide rate was observed across the EU-27 countries,
with only the exceptions of Malta, Poland and Portugal where
increasing trends were present [1]. Despite the onset of the
economic crisis, there is no strong evidence that national suicide
rates have increased but suicide remains a major public health
problem, accounting for 60.000 deaths per year in the EU-27
alone [1].
Suicide is strongly associated with poor mental health, especially
mood disorders [3].
Antidepressants are the most common treatment for mood
disorders, but effective use of these medications requires admin-
istration to patients who have been properly diagnosed and then
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adequately followed-up [4,5]. There is a consensus as to the
importance of primary care doctors’ education programmes for
improving the management of depression with antidepressants in
order to reduce the risk of suicide [6]. Furthermore, a number of
multi-component suicide prevention programmes emphasise the
crucial importance of primary care education programmes to
facilitate optimal antidepressant prescribing [7].
However, there are concerns about the efficacy and safety of
antidepressants, with some authors suggesting that these medica-
tions are at best no better than placebo [8] and others that
antidepressants may actually increase the risk of suicidal behav-
iour, particularly in young people [9–11]. In contrast, still other
authors contend that there is a bias in these findings and that
benefits are in fact greater than risk [12–16]. For instance, one
meta-analysis of 27 RCT trials examined antidepressant prescrib-
ing in children and adolescents to age 18 with a diagnosis of major
depressive disorder and showed that benefits appeared to far
outweigh a small increased risk of suicidal behaviour [17].
The limited applicability of data from RCTs to public health
questions point to the importance of evidence from other types of
study design. For instance, analysis of US Veterans Affairs Medical
System record data of more than 200.000 adults diagnosed with
depression and followed up for at least six months, found
statistically significant lower rates of suicide in those treated using
any antidepressant [18]. Comparisons among such studies with
very different approaches are difficult. Studies vary in basic
terminology, definition of outcomes and time periods considered,
drugs and other interventions assessed, and statistical methods,
leading to seemingly contradictory results. For instance, one
review of studies with naturalistic designs had equivocal findings
[19]. In contrast, a number of studies of the effects of warnings on
the risk of suicide with use of antidepressants on subsequent usage
observed an increase in suicide rates in younger people [19].
Furthermore, differing approaches in these studies to controlling
for potential confounds are challenging for integration and
interpretation. In some settings and contexts, economic develop-
ment correlates with lower suicide rates [20,21], while alcohol
consumption [22–24], divorce both in men and women [25,26]
and unemployment [27,28] can correlate with higher suicide rates.
Nonetheless, there is potentially an important role for ecological
studies, i.e., studies analysing data trends at a population rather
than an individual level, to help to inform public health policy.
This is advantageous where multiple areas or countries can be
examined, in order to control better for region-specific factors that
may impact on suicide rates and use of mental health services. The
evidence from these studies is, however, also mixed. One review of
19 ecological studies found equivocal evidence for links between
suicide and antidepressants, with slightly greater reductions in
suicide rates in the 1990s compared to the 1980s, especially when
associated with higher initial suicide rates, being a man and older
age [29].
Wheeler et al [30] examined changes in country-specific suicide
trends in younger people following the introduction of regulatory
actions including the use of warnings on antidepressants in a
number of countries in 2003 and 2004. They also found the
evidence to be equivocal with reductions in the rate of suicide
observed in some countries and increases in others, albeit noting
weak evidence of an increase in suicide in young women.
Ludwig and Marcotte [31] pooled panel data concerning rates
of suicide and the increased use of SSRI’s from the US, Canada,
Australia and 24 European countries between 1980 and 2000 and
estimated that overall an increase in sales of one pill per capita was
found to be associated with a 2.5% decrease in suicide rates for the
whole population. However, they acknowledged that this finding
was qualified by SSRI sales data having to be imputed prior to
1990 due to a lack of sales data. Nonetheless, their finding suggests
that greater utilization of SSRI, particularly for adults, might be a
cost effective strategy from a public health perspective, with one
suicide averted for every 300,000 pills sold. The same authors also
undertook further analysis with panel data covering the same time
period for 26 countries, including seven countries from central and
Latin America, Japan, Israel, 13 EEA countries, the US, Canada,
Australia and New Zealand. The conclusions were much the same,
although a more powerful effect was shown with one suicide
averted for every 200,000 pills sold. This analysis also noted that
there was no evidence in any change in patterns of psychotherapy
over the study period [32].
Thus, a number of previous studies have used an ecological
approach to look at some actions to help reduce the risk of suicide.
Notwithstanding long held arguments on ‘ecological fallacy’ and
the danger of misinterpretation of findings of studies gathered
using population level data [33,34], there are at least three reasons
for a greater use of this type of study design in respect of suicide
research.
First, escalating costs associated with increasing use of
antidepressants in many countries suggests the need to examine
long term effectiveness of antidepressants both in terms of a
reduced prevalence of mood disorders or reduced incidence of
suicide. The value of antidepressant treatment at a population-
health level has been challenged [35,36] and remains to be
demonstrated. Second, in order to demonstrate statistically in a
controlled study that antidepressants produce a preventive effect in
respect of the profound but nonetheless relatively rare event of a
completed suicide, we would need a sample size of 20.000 people
randomly treated with either antidepressants or placebo [37]. This
may be difficult to achieve in practice given that suicidal risk tends
to be an exclusion criterion in antidepressant trials, naturalistic or
experimental. Third, it would be unacceptable for ethical reasons
to conduct a randomized controlled trial with suicide as an
outcome variable [38,39].
Objectives
Given the continued debate on whether evidence of substantial
increases in the rate of antidepressant prescription can be
translated into improved public health outcomes, and notably
reduction in suicide, the present study aims to describe antide-
pressant utilization and suicide trends in European, largely EU,
Member States.
Our first aim was to examine whether the growing use of
antidepressants had an effect on European suicide rates, exploring
the plausibility of competing explanations of associations with
indicators such as adult per capita alcohol consumption, unem-
ployment and divorce rates, and GDP. Our second aim was to
examine temporal relationships, i.e. whether any reduction in the
rate of suicide preceded any trend towards increased use of
antidepressants as revealed by shorter and longer time-series of
simultaneous antidepressant utilization and suicide data.
Methods
Sources of Data
This ecological and naturalistic study analyses correlations
between datasets over a lengthy time period, covering 29
European countries including all 27 European Union Member
States, with the exceptions of Malta and Cyprus, due to a lack of
data on antidepressant utilisation in those countries. Data from
Croatia, Iceland, Norway and Switzerland were also included.
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Figure 1. Suicide and use of antidepressants, by country, more than 19 years of simultaneous data (P.75).
doi:10.1371/journal.pone.0066455.g001
Table 2. Pearson correlations between last 5-years means of DDD/1000/day and SDR suicide, million population and number of
suicide deaths within quartiles of countries by years of SDR suicide and DDD/1000/d simultaneous data.
all
countries countries by quartiles
19 or more years (P.75) 15 to 19 years (P50–75) 7 to 14 years (P25–50) 6 or less years (P,25)
Countries
Czech Republic,
Denmark, Finland,
Germany, Iceland,
Norway, Sweden
Austria, Hungary,
Italy, Portugal, Spain,
UK
Estonia, France, Greece,
Ireland, Lithuania,
Luxembourg,
Netherlands, Slovakia
Belgium, Bulgaria,
Croatia, Latvia, Poland,
Romania, Slovenia,
Switzerland
DDD/1000/day and
SDR Pearson correlation
–.41*** –.53*** –.46*** –.48*** .28
SDR – last 5 years
available mean
12.94 12.08 10.15 14.21 15.33
DDD/1000/day – last
5 years available mean
40.01 58.41 46.30 34.70 27.82
Mid-year population
–2009
514.1 117.7 196.9 105.2 94.3
Suicide deaths –
last year available
60.903 14.563 16.508 14.857 14.975
***p#.001.
doi:10.1371/journal.pone.0066455.t002
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Figure 2. Suicide and use of antidepressants, by country, 15 to 19 years of simultaneous data (P50–75).
doi:10.1371/journal.pone.0066455.g002
Figure 3. Suicide and use of antidepressants, by country, 7 to 14 years of simultaneous data (P25–50).
doi:10.1371/journal.pone.0066455.g003
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Completed suicide data were obtained from the WHO Health
for All European Mortality Database (WHO-MDB) [40]. This
consisted of SDR for all cases of suicides (ICD10 codes X60–X84
and ICD9 codes E950–E959) for each available year for the period
1980–2009. We assumed the suicide recording procedures
remained the same in the countries involved throughout the study
period [41]. Population data and national unemployment rates
were obtained from the WHO European Region Health For All
Database (HFA-DB) [42]. Unemployment comprised all working
age individuals out of work, currently available for work, or
seeking work. GDP in US$ per capita was also obtained from the
WHO HFA-DB [42]. Alcohol intake, defined as recorded adult
(15+ years) per capita consumption of pure alcohol (APC) was
obtained from the WHO Global Information System on Alcohol
and Health (GISAH) [43]. The recorded crude divorce rate per
1000 population was obtained from OECD Social Indicators [44].
The defined daily dosage (DDD) of a drug for adults is
determined by an independent scientific committee making use of
the WHO Collaborating Centre for Drug Statistics Methodology
[45]. Data on DDD per thousand individuals per day (DDD/
1000/day) for antidepressants were used in the analysis. This data
provides a rough estimate of use of these drugs and the proportion
of the population receiving treatment with a particular antide-
pressant on a daily basis. Only antidepressants in class N06 of the
Anatomical Therapeutic Chemical Classification System (ATC)
were included in the analysis [45]. Other ATC drugs classes were
excluded, such as lithium, bupropion, combination with antipsy-
chotics and herbal remedies for depression such as St John’s Wort
(hypericum perforatum), because of a lack of data on consumption
and/or consensus on average daily effective dose.
In order to maximise time series data on antidepressant use in
each country over the period from 1990 to 2009, three different
DDD/1000/day data sources were used. Total wholesale figures
were obtained from IMS Health for the period 2004–2009 (1995–
2009 for Portugal and 1996–2009 for Ireland) and OECD
pharmacy sales data for the period 1990–2009 [46]. Data from
national statistical offices and published literature for 1990–2009
were also used.
Country data from both the IMS and OECD were used
wherever possible. For Bulgaria, Croatia, Ireland, Latvia, Poland,
Romania and Switzerland only IMS Health data were available.
Units of antidepressants sold each year in the IMS database were
converted into kilogrammes of active ingredient in order to
establish the total quantity of sold defined daily dose (DDDs),
which were then divided by the country mid-year resident
population, in order to obtain global DDD/1000/day. Using this
procedure, we obtained units for total antidepressants, including
tricyclic, atypical, SSRIs, Serotonin–norepinephrine reuptake
inhibitors (SNRIs) and other antidepressants.
For Iceland, the Netherlands and Slovenia, OECD pharmacy
sales DDD/1000/day data was the only available source. In
addition to data from IMS and OECD, other DDD/1000/day
data were obtained from the published literature, namely in the
case of Austria [47], Hungary [48–50], and Italy [51] and directly
from authors, as in the case of Denmark, Finland, Norway and
Sweden [38,52].
Figure 4. Suicide and use of antidepressants, by country, 6 or less years of simultaneous data (P,25).
doi:10.1371/journal.pone.0066455.g004
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Where there was overlap in available information covering the
same time period in any country, DDD/1000/day data were
correlated to assess for consistency. After obtaining a very strong
positive correlational analysis (r = .98) from these different sources,
averaged DDD/1000/day were used in the analysis.
Statistical Analyses
The final analyses were performed using 870 observations from
29 countries covering varying timeframes ranging from a
maximum of 30 years (1980 to 2009) to just 4 years for
antidepressant utilization in Slovenia. There was at least 20 years
data for suicide rates in all countries, with 18 countries having data
for all 30 years (Table 1). Rate of use for antidepressants and
completed suicides in the first and last years for which data are
available are presented, along with average annual trend data for
each five year period covered. We did not use extrapolations based
on available trends in consumption to estimate likely consumption
of antidepressants for years where data were not available.
We examined the strength of the association between SDRs for
suicide and the use of antidepressants measured in DDD/1000/
day using Pearson’s correlation coefficient. We also used Pearson’s
correlation coefficient to examine the direction and magnitude of
associations between suicide SDRs or DDD/1000/day respec-
tively and GDP, alcohol consumption, unemployment and divorce
rates. We did not consider statistical significance because there are
correlated measures within each individual country and indepen-
dent measures in different countries. Therefore, p-values can only
be obtained correctly through the use of a general linear mixed
model, which we discuss below. This requires taking longitudinal
co-variation between measures into account.
General linear mixed models (GLMM) combine the properties
of linear mixed models which incorporate random effects and
generalized linear models which contain non-normal data. The
choice of a general linear mixed model (GLMM) allows for the
correlation of observations and analysis of incomplete longitudinal
data. It is a statistical method for modeling outcome measures as a
function of fixed (population) effects, while simultaneously
modeling individual subject parameters as random effects, and
can accommodate time-dependent covariates as well as missing
observations [53].
The GLMM is represented by
Yi~XibzZidizei
Table 3. Magnitude of correlations between suicide SDR and antidepressant utilization and potentially confounding variables.
Country DDD/1000/day GDP Alcohol Unemployment Divorce
Austria –.97 –.94 –.05 –.66 –.92
Germany –.96 –.77 .83 –.71 –.86
Hungary –.96 –.86 .90 .18 .46
Estonia –.96 –.78 –.88 .09 .72
Italy –.94 –.81 .69 .66 –.81
Sweden –.89 –.82 –.26 –.72 .03
Finland –.89 –.66 –.54 –.04 –.09
Lithuania –.88 –.67 –.33 .32
France –.87 –.86 .81 .02 –.54
UK –.86 –.90 –.82 .77 .43
Norway –.85 –.75 –.66 –.22 –.35
Denmark –.84 –.89 .30 .65 .37
Slovenia –.82 –.97 .27 –.22 –.48
Czech Republic –.80 –.85 –.75 –.84 –.43
Slovakia –.78 –.87 .47 –.26 –.79
Croatia –.75 –.87 .34 –.10
Spain –.73 .12 –.67 .42 .30
Bulgaria –.66 –.84 .01 .42
Ireland –.65 .38 .75 –.45 –.56
Romania –.65 –.40 –.12 .65
Belgium –.62 –.78 .80 .59 –.57
Switzerland –.59 –.93 .94 –.72 –.79
Latvia –.56 –.68 .07 –.36
Netherlands –.48 –.86 .82 .89 .29
Greece –.44 –.70 .57 –.54 –.52
Iceland –.12 –.32 –.27 –.40 .26
Poland –.08 .09 –.36 .56 –.31
Luxembourg –.01 –.63 –.46 –.60 –.27
Portugal .50 –.33 .46 .40 –.25
doi:10.1371/journal.pone.0066455.t003
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where Yi is an ni61 vector of ni observations on the i-th subject; b
is a p61 vector of known, fixed, population parameters; Xi is an
ni6p known, constant design matrix for the i-th subject; and di is a
q61 vector of unknown, random individual parameters. The
random parameters are subject-specific but the vector size is the
same from subject to subject; Zi is an ni6q known, constant design
matrix for the i-th subject corresponding to the random effects di;
and ei is an ni61 vector of random errors terms.
The GLMM is unstructured in relation to time frame, since the
series of available years of data vary from country to country. The
country is taken as the subject and a random effect, with DDD/
1000/day, GDP, alcohol, unemployment and divorce as fixed
effects, year as a repeating variable and suicide SDR as the
dependent variable. The year of data observation was not
considered a fixed effect because of its anticipated strong
explanatory power for variations in suicide observations, which
would prevent analysis of the role of other variables. This is also
the reason we did not use time series.
In line with previous work looking at temporal patterns in
fluoxetine prescribing and suicide rates in the US [54], co-variance
analyses were performed according to first order auto-regressive
(AR) models of aggregate time-series data to adjust for serial
correlation in time series for each predictor (antidepressant use,
GDP, alcohol consumption, and divorce and unemployment
rates).
In order to assess the consistency of the GLMM results, we also
performed a Poisson regression, an approach used in a number of
previous studies [55–57]. In this case suicide SDR was the
dependent variable, with DDD/1000/day as the predictor and a
logarithm of base n of the number of years of available data per
country, with an analysis of effects of Type III tests. To do this we
cleaned the original database of years simultaneously without
suicide SDR and DDD/1000/day, data were grouped by country,
and the logarithm of base n time was created.
Finally, to compare the effect of changes in the use of
antidepressants on suicide rates between two time periods,
1980–1994 and 1995–2009, an analysis was performed with an
AR adjusted model, using DDD/1000/day as the independent
variable and testing the interaction of DDD/1000/day and time
period. Significance was set at p#0.05 (two tailed). This
demarcation of 1994, was chosen because it is the point where
SSRIs started to become available and so, it was expected to mark
an acceleration in the increase of DDD/1000/day over the
subsequent 15 years.
Statistical analysis was done using SPSS software, version 17.0.
Ethics Statement
These data are publicly accessible, with the exception of IMS
Health, and are aggregated at the population-level. Individual-
level information, for instance on individual patients, was
unobtainable and therefore all data were analyzed anonymously
without any privacy or confidentiality concerns. The Ethical
Commission of the Faculdade de Cieˆncias Me´dicas of Universi-
dade Nova de Lisboa (medical institutional review board) where
the two first authors are affiliated considers no review is needed if
the data are anonymous and administrative.
Results
Trends in the Use of Antidepressants
On average there was 15 years of antidepressant utilisation data
available in the 29 countries. There were marked differences: those
countries with six or fewer years observations, with the exception
of Switzerland, were all countries that have joined the EU since
2004 (Bulgaria, Latvia, Poland, Slovenia and Romania) or are in
the process of joining (Croatia).
Table 4. Magnitude of correlations between DDD/1000/day
and the other potentially confounding variables.
Country GDP Alcohol Unemployment Divorce
Austria .80 –.91 .57 .81
Belgium .92 –.79 –.65 .75
Bulgaria .81 .26 –.17
Croatia .94 .99 –.91
Czech Republic .98 .80 .60 .37
Denmark .91 –.44 –.86 –.03
Estonia .92 .97 –.72 –.83
Finland .89 .76 .21 .49
France .71 –.60 –.84 .57
Germany .88 –.63 .69 .65
Greece .94 –.26 –.83 .90
Hungary .92 –.47 –.18 .61
Iceland .79 .92 –.04 –.52
Ireland .92 .73 –.31 .77
Italy .88 –.91 –.97 .94
Latvia .97 .95 .29
Lithuania .95 .60 –.45
Luxembourg .90 –.48 .85 .13
Netherlands .94 –.91 .39 –.73
Norway .89 .81 .20 .48
Poland .87 .78 –.85 .39
Portugal .96 –.84 .64 .84
Romania .81 .66 –.27
Slovakia .97 .54 –.43 .95
Slovenia .80 –.95 –.78 1.00
Spain .92 –.87 –.78 .88
Sweden .85 .52 .54 –.21
Switzerland .94 .46 –1.00 .20
UK .90 .82 –.92 –.78
doi:10.1371/journal.pone.0066455.t004
Table 5. Model estimates of fixed-effects with SDR suicide
rate as outcome.
Regression
coefficient SE T p-value
Model 1
DDD/1000/day –.070 .022 –3.162 .002
Model 2
DDD/1000/day –.088 .026 –3.327 .001
GDP .018 .026 .707 .480
Alcohol .129 .159 .809 .419
Unemployment –.015 .064 –.232 .816
Divorce 1.273 .473 2.692 .007
doi:10.1371/journal.pone.0066455.t005
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Data on the use of antidepressants are presented in Tables 1 and
2. Overall there has been an increase of 40.33 units DDD/1000/
day in the study period, equal to the weighted-average difference
between the first and last years of DDD/1000/day in each
country, from an average of 13.69 to 43.91 in the first and last year
of availability respectively. Our data indicates continuous growth
in the use of antidepressants over time, albeit varying across
countries, but with an average growth per annum of 19.83% in
DDD/1000/per day. The lowest rates of annual growth of just 3%
were seen in the Netherlands and Switzerland followed by
Bulgaria, France and Luxembourg (all 5%), with the highest
growth rate of 59% seen in Finland followed by the Czech
Republic (41%), Slovakia (40%) and Sweden (34%).
The latest available five year data indicate that the use of
antidepressants varies markedly from just 4.02 DDD/1000 per
day in Romania, 5.59 in Latvia and 6.03 in Bulgaria, to as much
as 68.50 in Denmark, 70.09 in Sweden and 95.16 in Iceland.
There was an average DDD/1000/per day of 40.01 across all
countries.
Suicide Trends
Suicide trends are presented in Tables 1 and 2. Over the study
period, SDR rates for suicide decreased by a weighted average of
6.16, from an average SDR of 19.06 for the first year available to
12.93 in the last year available, notwithstanding variations in the
years of data available in countries. The mean decrease in the
SDR rate was 0.81%. There was little difference in the mean SDR
rate for the last five years of data at 12.94.
Marked differences remained in suicide SDR rates across
Europe, yet there was also a high degree of consistency in those
countries with the lowest and highest rates of suicide over the study
period. For the initial years of observation the highest rates were
seen in Hungary (44.54), Estonia (36.74) and Lithuania (35.16),
with the lowest rates seen in Greece (3.2), Spain (4.69) and Italy
(7.15). For the last year of observation the highest SDR rates were
seen in Lithuania (31.47), Hungary (21.79) and Latvia (20.7).
Similarly the lowest rates were seen in Greece (3.02), Italy (5.39)
and Spain (6.34).
Only Poland, Spain and Ireland had annual suicide rates higher
in the last year compared with the initial year of observation.
There was also little change in Greece, Iceland, Norway, Portugal
and Romania but in all cases SDR rates were below the mean rate
for all 29 countries. The highest rates of reduction were seen in
Denmark, Estonia, Germany, Hungary, Slovakia, Slovenia and
Switzerland.
Correlation between Suicide and Utilization of
Antidepressants
As Table 2 indicates, countries were grouped in quartiles by the
availability of annual data on DDD/1000/day and SDR for
suicides. A non-significant correlation was observable in countries
with 6 or less years of both DDD and SDR data (r = .28; NS), they
had the highest mean SDR suicide rate and the lowest DDD/
1000/year for the last five year period, but covered less than a fifth
of the population under study and less than a quarter of suicides in
the last available year. For all other quartiles there is an inverse
statistically significant correlation, with an increasing use of
antidepressants and greater reductions in the suicide SDR.
Figures 1–4 plot suicide SDR and the use of antidepressants for
the same country quartiles. In almost all countries, an increase of
DDD/1000/day seems to correspond with a decrease in suicide
SDR, although in countries where suicide rates are already low,
antidepressants appear to have less impact. At first sight, the
notable exceptions are Iceland (Figure 1), Portugal (Figure 2), and
Luxembourg (Figure 3) whereas for the countries in Figure 4 the
paramount characteristic is the lack of antidepressant utilization
data.
Association between Suicide and Use of Antidepressants
with GDP, Alcohol, Unemployment and Divorce
We assessed the magnitude and direction of correlations in each
individual country in an exploratory analysis with Pearson’s
correlation coefficients. As Table 3 indicates, an inverse correla-
tion was observable in all countries between SDR for suicide and
DDD/1000/day, with the exception of Portugal. There was also
an inverse correlation with GDP, with the exceptions of Ireland,
Poland and Spain. As Table 4 indicates there is also a consistent
direction and magnitude of correlation between DDD/1000/day
and GDP in all 29 countries. No strong patterns are seen in either
Tables 3 or 4 in respect of SDR and alcohol, unemployment or
divorce.
Effects of Use of Antidepressants, GDP, Alcohol
Consumption, Unemployment and Divorce on Suicide
The GLMM with DDD/1000/day as the only predictor of
suicide rates (model 1) and with all independent variables as
predictors (model 2) are displayed in Table 5. Model 1 revealed a
significant effect of DDD/1000/per day (p = 0.002). In Model 2
DDD/1000/day still presents a significant effect on SDR suicide
when adjusting for the other independent variables (p = 0.001). In
this model an increase of one unit in DDD/1000/day, adjusted to
the remnant independent variables, diminishes suicide SDR by
0.088 units. Divorce also appears to have a significant effect on
Table 7. Model estimates with total suicide rate as outcome
and the interaction with period.
Regression
coefficient SE T p-value
DDD/1000/day –.479 .066 –7.232 ,.001
Period –6.991 .714 –9.791 ,.001
DDD/1000/day6Period .413 .064 6.460 ,.001
doi:10.1371/journal.pone.0066455.t007
Table 6. Poisson distribution regression with SDR suicide rate as outcome.
Regression
coefficient SE 95% Wald confidence interval p-value
Lower Upper
DDD/1000/day –.00018 .00004 –.00026 –.00010 ,.001
doi:10.1371/journal.pone.0066455.t006
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SDR for suicide in this model (p = .007). An increase of one unit in
the divorce rate, increases the SDR by 1.273.
In Table 6 we present a Poisson distribution regression model
where DDD/1000/day presents a significant, though only modest,
effect on suicide SDR. The model has an adequate goodness of fit
with a chi-square (27) = 1.118,83 inferior to the critical value for
a= .001 and the Omnibus Test, a likelihood chi-squared test, is
statistically significant.
We do not present a Poisson model with the other independent
variables because of a high level of missing data after cleaning the
database for empty cells: the number of observations was 870 in
the GLMM but there are only 429 observations for suicide SDR
and DDD/1000/year with Poisson regression. These would only
be 311 observations when considering all independent variables.
Effects of Antidepressant Utilization on Suicide Rates in
Different Time Periods
Table 7 presents the results of our analysis comparing the
effect of DDD/1000/day on suicide rates for two different time
periods. This is a mixed model not structured within time, with
countries with random effect, with DDD/1000/day and two
periods (1980–1994 and 1995–2009) as fixed effects, with an
interaction between DDD/1000/day and period, and year as a
repeating factor. An effect modification between the two periods
is observable since the interaction is very significant (p,0.001).
In the period 1980–1994, the effect of DDD/1000/day on
suicide SDR was –0.479, and –0.066 (–0.479+0.413) in the
second time period. Thus there was a negative impact on suicide
rates in both time periods, though this was much more
pronounced for 1980–1994.
Discussion
Main Results
Our analysis indicated that for 15 years of data on average for
the 29 countries included in our study, the use of antidepressants
increased on average by 19.83% per year. By the end of this time
period for the whole study area there had been an average increase
of 40.33 units of DDD/1000/day. Over a mean period of 28
years, the overall SDR for suicide decreased at a rate of 0.81% per
year, corresponding to a reduction of 6.16 in the SDR rate for
suicide. There was a strong inverse correlation between these
trends.
How much of this increase of antidepressant use is needed to
reduce the rate of suicide? A classical study from Sweden by
Isacsson [38] covering the period from 1978 to 1996 found that
suicide rates decreased consistent with a hypothesis that if the use
of antidepressant medication increased five-fold, suicide rates
would decrease by 25% assuming that depression treatment
prevalence was approximately 1% and point prevalence of major
depression was 5%. We have also already noted that in the large
multi-national studies by Ludwig and Marcotte covering the
period from 1980 to 2000 [31,32], that an increase in SSRI sales
of one pill per capita is associated with a decline in suicide rates of
between 2.5% and 5% in different groups of countries around the
world.
The total population of the 29 European countries in our study
was 514.1 million in 2009. If 10 DDD/1000/day corresponds
approximately to 1% of population treatment point prevalence
[58], our data suggests that there could have been an increase in
treatment for depression of 4% of this population correlating with
a saving of 31.670 deaths by suicide in the last year covered,
equivalent to 650 people treated for each life saved, per year.
Portugal is the only country where there is a positive correlation
between DDD/1000/day and suicide SDR, considering the actual
large utilization of antidepressants. This can possibly be explain-
able by the lack of precision of suicide register and over-estimation
of undetermined violent deaths concealing suicides [41,59]. The
small populations of both Luxembourg and Iceland and therefore
the small numbers of suicides recorded, probably accounts for the
lack of any relationship with high antidepressant utilization. In
other countries, such as Greece or Ireland, there was a sharp
increase in DDD/1000/day and little change in suicide was
apparent though a clear negative correlation was present. Perhaps
in Greece, with an already very low suicide rate along the period a
ceiling effect is present whereas in Ireland suicide is more frequent
in young and middle aged men, who typically present an
unfavourable help-seeking behaviour [60].
Another key result was the demonstration of how the impact of
antidepressant utilization on suicide changes as more annual
information becomes available on both DDD/1000/day and SDR
suicide: a longer series of data means a stronger correlation
between lower SDR for suicide and higher DDD/1000/day. This
suggest that those countries in this study with less than 6-years of
both types of data that did not show a significant inverse
correlation between these indicators may well in future demon-
strate this finding as more data becomes available. Previous
published studies with negative results should be analysed in view
of this contingency.
A third important result was that two different regression
statistics confirmed that DDD/1000/day is an explanatory factor
for suicide SDR, notwithstanding that the Poisson regression
meant reducing analysed observations from 870 to 426, therefore
reducing accuracy in relation to the GLMM. Though we cannot
assume a causal effect, when adjusting for other independent
variables, adequate GLMM modelling makes DDD/1000/day an
explanatory factor for changes in the suicide SDR: a one unit
increase of DDD/1000/day seems to diminish the suicide SDR by
0.088 units.
A clear covariance is observable, at the country level, between
potentially explanatory suicide factors such as antidepressant
utilisation, GDP, alcohol consumption, unemployment and
divorce, suggesting a differential impact on countries and implying
GLMM and Poisson regressions were appropriate models for
estimation.
The fourth key result was the demonstration that DDD/1000/
day had an effect on SDR for suicide both between 1980 and 1994
and in the subsequent 15 years. With increasing DDD/1000/year,
suicide-related SDR was expected to decrease. However, this
decreasing trend decelerates over time: the analysis suggests that in
the first period, where in most cases high rates of suicide SDRs
were seen, less of an increase in the use of antidepressants would
be necessary to reduce suicide SDR whereas in the subsequent
period, when suicide SDRs had become lower in most countries, a
much higher rate of antidepressant utilization would be necessary
to further reduce suicide SDR. Suicide-related SDR continued to
decline in the second 15-year period, albeit at a much reduced
rate. More importantly, nevertheless, it suggests that antidepres-
sant utilization DDD/1000/day increase had an important effect
in suicide SDR from the start, when suicide SDR started to lower
in Europe. This rebuffs most criticisms and scepticism on
observable antidepressant effects on suicide decrease, usually
stating that suicide had already started to decrease before
antidepressant utilization exploded, in the nineties, therefore
denying earlier generation antidepressant effects.
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Previous Studies
This study is similar to those of Ludwig and Marcotte [31,32]
since the observation unit is the country. Nevertheless, it presents
several characteristics that might be seen as advantageous in
relation to the generalisability of results. First, it draws on a more
homogeneous set of countries, albeit with some substantial
differences in GDP, infrastructures and historical development of
countries that had formerly been part of the Soviet bloc prior to
1990. Second, it covers more consecutive years of effects versus
each 5 year calculation (average 15 years against 10 years, since in
Ludwig and Marcotte’s studies for 1980–1990 SSRI pills are
extrapolated), the almost global extension of antidepressants (and
not only of SSRIs), the use of DDD/1000/day, which is a measure
of antidepressant utilization independent of national regulations,
costs and commercial specificities, allowing for comparisons, and
that can be related to utilization needs and treated prevalence. As
previously explained, one DDD may be sufficient for one person-
day of adequate treatment, and 10 DDDs per 1000 inhabitants per
day is therefore considered to represent approximately a 1% point
treated prevalence [58] though we cannot assume users take
medication as prescribed.
This study has also many advantages over single national
studies, though it does not substitute for them: it controls for the
variability of factors that affect suicide rates at the country level
and it has more explanatory power on the role of antidepressants
on suicide rates because of the number of observations involved.
We also believe it purports more power than reviews and meta-
analysis produced so far because of its consistency: close
geographic and socio-political context in the last 10 years, use of
available annual data series, inclusion of all families of antide-
pressants and use of DDD/1000/day.
In fact, single studies and reviews [29] have used several
definitions of antidepressant utilization, including costs, number of
packages or pills sold, number of prescriptions issued, defined daily
dosage (DDD) and defined daily doses per thousand individuals
per day (DDD/1000/day). These discrepancies hinder compara-
bility and introduce probable sources of bias because drug costs,
pills dosages, quantities of pills per package and prescriptions,
might oscillate longitudinally because of external, regulatory and
commercial reasons. Using DDD/1000/day represents a stable
variable for the estimation of the exposure to drugs and the
proportion of the population that may receive treatment with a
particular drug on a daily basis [45].
Another source of bias in some previous studies has been
associated with a major focus on SSRIs, and not on the analysis of
the use of the whole class of antidepressants, including SNRIs,
atypicals and tryciclics. Patterns in the use of these drugs might
vary considerably across countries.
Moreover, these studies present substantial differences in the
periods of time that are analysed, both for antidepressant use and
recorded suicides, from as low as 2 years to as high as 30 years for
antidepressant use utilization series, and a similar but slightly
better pattern for suicide time series. It is likely that these
variations will have had an impact on results, as well as making
meaningful comparison difficult.
The extent to which data series are available across countries for
the same time periods can influence correlation results strikingly.
This is quite important to assess previous and future studies: results
are far more reliable when longer yearly time series are present.
Our study presents an average of 15 years of both annual suicide
and antidepressant utilization data, the largest figure to our
knowledge, albeit hampered by inconsistent time series data for
antidepressant utilization across countries. There is also consider-
able variability of statistical procedures within studies published so
far, which further complicates comparing results. Most studies
present differing correlations, linear regressions, Poisson regres-
sions and time series; we avoid this problem in our multi-country
analysis.
Ecological Design Considerations
Because this is an ecological study, we emphasise that we cannot
depict causal links and therefore these results must be interpreted
with great caution. Nevertheless, as argued earlier, we believe that
there is a case for this study design because there is a need to
validate the effectiveness and potential cost effectiveness of
antidepressants as an intervention for suicide prevention. As
suicide is a comparatively rare event, it would be very difficult to
study in a controlled trial, not to mention any of the potential
ethical concerns that might arise in trial design [38,39]. Trials are
also unlikely to be of a sufficiently long timeframe for adequate
analysis of impacts on suicide, where data covering many years is
required. Thus ecological studies still have a place in the
evaluation of some interventions, namely public health interven-
tions. As in this case, conclusions drawn do not uncover causal
links but must be taken in view of knowledge available, face
validity and plain common sense.
The debate on suicide-antidepressant trends at the public health
level might be seen as disproportionate since the methodological
and interpretation problems that arise are present in all ecological
studies exploring any kind of correlations. For instance, there have
been positive developments in mental health services policy,
delivery and provision in Europe in recent decades [61] but the
impact of mental health services provision on suicide rates assessed
through ecological studies has produced mixed results [47,48,62–
68]. Nevertheless, it would hardly be arguable not to implement
good practices and optimise mental health services when resources
are available.
Confounding Effects
The association between alcohol consumption, unemployment,
and divorce and suicide was inconsistent across the different
countries in our analysis. How can an inverse correlation between
these variables and the suicide rate in some countries be
interpreted, when a positive correlation was expected?
Considering alcohol consumption, even though patterns of
alcohol use differ from culture to culture, it is known that alcohol
abuse can contribute to an increased risk of suicidal behavior
[24,69]. Therefore, it would be expected that a reduction in
suicide would be accompanied by a reduction in alcohol intake
[70]. Notwithstanding, in Hungary, between 1990 and 1998
alcohol sales increased by 25% and suicide rates dropped by 20%
[48] and in a Hungarian suicide prevention project, the
intervention region had a higher alcohol-related death rate both
before and after the program compared with the control region.
Moreover, there was a decrease in alcohol-related deaths over time
in both regions, and the expected improvement in the intervention
region was not confirmed [71].
Also, in a previous study performed in 1980–1982 in Portugal,
the inverse association between suicide rates and alcohol cirrhosis
deaths had a distinctive regional distribution: whereas in the north,
alcohol uptake and cirrhosis death was greater than in the south,
suicide rates were much greater in the south [22], suggesting that
alcohol addiction is on many occasions either a depression
equivalent or a self-medication strategy [24]. Overall, cultural
differences are also important in explaining variation in the
associations across countries.
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Explanations for Increased Prescribing of Antidepressants
Along with the perceptions of newer antidepressants of being
safer and easier clinically to manage, the past 30 years has been
characterized by depression awareness campaigns and more
extensive medical training concerning depression and suicide
[48]. Training for primary care and other medical personnel
concerning depression and suicide risk management has been a
core component of many suicide prevention programmes in
Europe since the implementation of the Gotland study [7,72–75].
Moreover, there is increased awareness of the extent of the impact
of poor mental health and the increased need for treatment and
support in Europe [76,77], varying from country to country [78],
that may also contribute to this increase in antidepressant
prescribing. Finally, there has been some increased funding for
mental health systems during the observation period. This may
have helped make antidepressants, along with other treatments for
depression more accessible [79].
Limitations
There are a number of limitations to this analysis. Utilisation is
only a proxy for rates of what occurs at the individual patient level:
we do not know if people take the medication they obtain, or if
they are taking less or more than the standard DDD. The real
rates of treatment of depression in Europe could conceivably be
lower than the high DDD/1000/day would suggest, taking in
account the multiple indications of antidepressants, frequent use of
higher dosages than the DDD, non-compliance, and co-therapy
with a second antidepressant [38]. Nor do we know the proportion
of individuals taking these medications that complete suicide. In
addition, we do not know the gender and age distribution of
antidepressant use, and so have not attempted to look at the
impacts of antidepressants on suicide rates by age or gender. We
also do not know the distribution of utilisation in relation to
severity of depression and anxiety disorders although some surveys
in Europe suggest the gap is greater in the lower end of severity,
and a recent meta-analysis suggests the value of antidepressants for
light and moderate as well as severe depression [80].
It should also be acknowledged that antidepressants are
prescribed for other mental health problems in addition to
depression (e.g. anxiety disorders, anorexia and bulimia nervosa,
ADHD), as well as for physical health problems (e.g. migraine
headaches, fibromyalgia, chronic pain) [81–83]. We also know
that poor physical health can be a risk factor for suicide [84].
Our analysis is also limited by focusing only on completed
suicides, but a proportion of undetermined deaths will also be due
to suicide; potentially including these data in our analysis might
impact on findings, particularly in countries such as Portugal and
Eastern Europe countries where undetermined deaths are
considerable. Future analysis should consider ‘probable suicide’
i.e. the sum of registered suicides and undetermined violent deaths.
Another limitation of our analysis is a lack of data on the use of
psychological therapies, alongside or as an alternative to the use of
antidepressants in treating depression and related disorders, and
therefore potentially contributing to the prevention of suicides.
Many of these limitations can only addressed through improve-
ments in epidemiological datasets, including more information
about treatment pathways; surveys might also be considered to
better obtain data on the use of antidepressants and other
medications, as well as other psychosocial therapies among specific
population sub-groups.
Nonetheless, despite these limitations and our caution over the
interpretation of our findings, the outcomes of the present study
underline the need to better optimise the appropriate use of
antidepressants as part of routine care, given that many people
who may benefit from their use do not receive them, while
conversely other individuals are inappropriately taking such
medications. Whether research projects, such as OSPI-Europe
that seek to foster a better quality of care, starting at the primary
care level, focusing on improved awareness of depression and risk
of suicide, appropriate antidepressant and other treatment
prescribing and monitoring, might produce such an effect will
require empirical demonstration.
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